I am a
Home I AM A Search Login

Papers of the Week

Papers: 17 Sep 2022 - 23 Sep 2022

2022 Sep 17

J Headache Pain



Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.


De Icco R, Vaghi G, Allena M, Ghiotto N, Guaschino E, Martinelli D, Ahmad L, Corrado M, Bighiani F, Tanganelli F, Bottiroli S, Cammarota F, Sances G, Tassorelli C
J Headache Pain. 2022 Sep 17; 23(1):123.
PMID: 36115947.


In Italy, monoclonal antibodies targeting the CGRP pathway are subsidized for the preventive treatment of high frequency and chronic migraine (CM) in patients with a MIgraine Disability ASsessment (MIDAS) score ≥ 11. Eligibility to treatment continuation requires a ≥ 50% MIDAS score reduction at three months (T3). In this study, we evaluate whether a ≥ 50% MIDAS score reduction at T3 is a reliable predictor of response to one-year erenumab treatment.